Paola Bisignano, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
DepartmentCardiovascular Research Inst
Address555 Mission Bay Blvd South
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Adelman JL, Ghezzi C, Bisignano P, Loo DD, Choe S, Abramson J, Rosenberg JM, Wright EM, Grabe M. Stochastic steps in secondary active sugar transport. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):E3960-6. PMID: 27325773; PMCID: PMC4941443 [Available on 01/05/17].
    2. Wardman JH, Gomes I, Bobeck EN, Stockert JA, Kapoor A, Bisignano P, Gupta A, Mezei M, Kumar S, Filizola M, Devi LA. Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake. Sci Signal. 2016 May 31; 9(430):ra55. PMID: 27245612.
      View in: PubMed
    3. Di Martino RM, De Simone A, Andrisano V, Bisignano P, Bisi A, Gobbi S, Rampa A, Fato R, Bergamini C, Perez DI, Martinez A, Bottegoni G, Cavalli A, Belluti F. Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3ß Inhibitors. J Med Chem. 2016 Jan 28; 59(2):531-44. PMID: 26696252.
      View in: PubMed
    4. Bottegoni G, Veronesi M, Bisignano P, Kacker P, Favia AD, Cavalli A. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments. ChemMedChem. 2016 Jun 20; 11(12):1259-63. PMID: 26663255.
      View in: PubMed
    5. Bisignano P, Burford NT, Shang Y, Marlow B, Livingston KE, Fenton AM, Rockwell K, Budenholzer L, Traynor JR, Gerritz SW, Alt A, Filizola M. Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the µ-Opioid Receptor. J Chem Inf Model. 2015 Sep 28; 55(9):1836-43. PMID: 26347990; PMCID: PMC4703110.
    6. Prati F, De Simone A, Bisignano P, Armirotti A, Summa M, Pizzirani D, Scarpelli R, Perez DI, Andrisano V, Perez-Castillo A, Monti B, Massenzio F, Polito L, Racchi M, Favia AD, Bottegoni G, Martinez A, Bolognesi ML, Cavalli A. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3ß inhibitors. Angew Chem Int Ed Engl. 2015 Jan 26; 54(5):1578-82. PMID: 25504761.
      View in: PubMed
    7. Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M. Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions. Biochemistry. 2014 Aug 12; 53(31):5140-9. PMID: 25073009; PMCID: PMC4131901.
    8. Bisignano P, Doerr S, Harvey MJ, Favia AD, Cavalli A, De Fabritiis G. Kinetic characterization of fragment binding in AmpC ß-lactamase by high-throughput molecular simulations. J Chem Inf Model. 2014 Feb 24; 54(2):362-6. PMID: 24444037.
      View in: PubMed
    9. Bisignano P, Lambruschini C, Bicego M, Murino V, Favia AD, Cavalli A. In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3ß. J Chem Inf Model. 2012 Dec 21; 52(12):3233-44. PMID: 23198830.
      View in: PubMed
    10. Gallina AM, Bisignano P, Bergamino M, Bordo D. PLI: a web-based tool for the comparison of protein-ligand interactions observed on PDB structures. Bioinformatics. 2013 Feb 01; 29(3):395-7. PMID: 23196990.
      View in: PubMed
    11. Favia AD, Bottegoni G, Nobeli I, Bisignano P, Cavalli A. SERAPhiC: a benchmark for in silico fragment-based drug design. J Chem Inf Model. 2011 Nov 28; 51(11):2882-96. PMID: 21936510.
      View in: PubMed
    12. Bisignano P, Moran O. Molecular dynamics analysis of the wild type and dF508 mutant structures of the human CFTR-nucleotide binding domain 1. Biochimie. 2010 Jan; 92(1):51-7. PMID: 19781595.
      View in: PubMed
    Paola's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.
    Back to TOP